ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1260

Hydroxychloroquine Reduces the Risk of Coronary Artery Disease in Patients with Rheumatoid Arthritis

Li Chun1, Mu Rong1, Su Yin1, Li Xiaofeng2, Wang Yongfu3, Wang Guochun4, Zhu Ping5, Liu Xiangyuan6, Chen Haiying7, Cui Liufu8, Zhang Zhuoli9, Li Zhenbin10, Li Junfang11, Zhang Fengxiao12, Han Shuling13, Lin Jinying14, Liu Xiaomin15, Hu Shaoxian16, Yang Xiuyan17, Huang Cibo Sr.18, Li Xingfu19, Wang Yi20 and Li Zhanguo1, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, Taiyuan, China, 3Department of Rheumatology and Immunology, Baotou, China, 4Department of Rheumatology and Immunology, Beijing, China, 5Department of Rheumatology and Immunology,Xijing Hospital, Xian, China, 6Department of Rheumatology and Immunology,Peking University Third Hospital, Beijing, China, 7Department of Rheumatology and Immunology,The Third Hospital of, Shijiazhuang, China, 8Department of Rheumatology and Immunology,Kailuan hospital of North China Coal Hospital, Tangshan, China, 9Department of Rheumatology and Immunology,Peking University First Hospital, Beijing, China, 10Department of Rheumatology and Immunology,Peace Hospital, Shijiazhuang, China, 11Department of Rheumatology and Immunology, Hebei Handan Central Hospital, Handan, China, 12Department of Rheumatology and Immunology,Hebei People's Hospital, China, 13Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing, China, 14Department of Rheumatology and Immunology,The people's hospital of guangxi zhuang autonomous region, Nanning, China, 15Department of Rheumatology and Immunology,Beijing shunyi hospital of China Medical University, Beijing, China, 16Department of Rheumatology and Immunology,Tongji Medical College Huazhong University of Science & Technology, Wuhan, China, 17Department of Rheumatology and Immunology,First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 18Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, 19.Department of Rheumatology and Immunology,Qilu Hospital of Shandong University, Jinan, China, 20Department of Rheumatology and Immunology,Second hospital of Lanzhou University, Lanzhou, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords:

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) can alter cardiovascular risk in RA by inflammation or by influencing cardiovascular risk factors indirectly. However, previous studies predominantly focused on methotrexate(MTX) and ignore the other major conventional DMARDs, such as hydroxychloroquine (HCQ).To assess the complication of coronary artery disease (CAD) and identify the risk factors of CAD in a large population of RA in China.

Methods: One thousand and ninety-six patients were enrolled in the study . Data were obtained from a retrospective survey of patients with RA, randomly selected from rheumatology practice of 21 university hospitals in China. The patients’ social conditions, clinical conditions, medications associated with RA such as DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoid, biologic agents were collected. The χ2test was used to compare the frequency of CAD risk factor, manifestations and medications of RA. Logistic regression modeling was used to examine the influence of risk factors on the development of CAD outcomes.

Results: Of the 1096 patients 34 developed CAD with a incidence of 3.1%. Compared to the control group, the CAD group patients had higher age (64.8±9.3yrs vs 52.0±14.1yrs,P=0.000), longer disease duration (13.3±11.4yrs vs 8.0±8.9yrs, P= 0.011), higher prevalence of diabetes mellitus (29.4% vs 7.0%,P=0.000) , hypertension (38.2% vs 16.2%,P=0.001), rheumatoid nodules (14.7% vs 2.7%,P=0.003) and lung interstitial disease (17.6% vs 7.0%,P=0.023). Patients with CAD were less likely to use hydroxychloroquine (HCQ)(5.9% vs 20.3%,P=0.038). Multivariate analysis showed higher age and rheumatoid nodules were independent predictors of CAD and HCQ was a protective factor of CAD .

Conclusion: CAD is a major concern for RA patients. HCQ reduces the risk of CAD in RA patients, higher age and rheumatoid nodules are independent risk factors for CAD in RA.

Disclosure:

L. Chun,
None;

M. Rong,
None;

S. Yin,
None;

L. Xiaofeng,
None;

W. Yongfu,
None;

W. Guochun,
None;

Z. Ping,
None;

L. Xiangyuan,
None;

C. Haiying,
None;

C. Liufu,
None;

Z. Zhuoli,
None;

L. Zhenbin,
None;

L. Junfang,
None;

Z. Fengxiao,
None;

H. Shuling,
None;

L. Jinying,
None;

L. Xiaomin,
None;

H. Shaoxian,
None;

Y. Xiuyan,
None;

H. Cibo Sr.,
None;

L. Xingfu,
None;

W. Yi,
None;

L. Zhanguo,
None.

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hydroxychloroquine-reduces-the-risk-of-coronary-artery-disease-in-patients-with-rheumatoid-arthritis/